021-51111890
购物车（）
sales@molnova.cn
ZLDI-8
CAS No. 667880-38-8
ZLDI-8 ( —— )
产品货号. M22943 CAS No. 667880-38-8
ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.ZLDI-8;?it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins.?
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥1361 | 有现货 |
|
| 5MG | ￥2341 | 有现货 |
|
| 10MG | ￥3686 | 有现货 |
|
| 25MG | ￥6099 | 有现货 |
|
| 50MG | ￥8586 | 有现货 |
|
| 100MG | ￥11583 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称ZLDI-8
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.ZLDI-8;?it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins.?
-
产品描述ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.ZLDI-8;?it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins.?ZLDI-8 treatment enhanced the susceptibility of HCC cells to a small molecular kinase inhibitor Sorafenib, and chemotherapy agents Etoposide and Paclitaxel.?ZLDI-8 treatment enhanced the effect of Sorafenib on inhibiting tumor growth in nude HCC-bearing mice model.?In nude HCC-bearing mice model, ZLDI-8 (0.2-2 mg/kg; intraperitoneal injection; every two days; for 20 days; nude mice) treatment enhances the effect of Sorafenib on inhibiting tumor growth.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体ADAM-17
-
研究领域——
-
适应症——
化学信息
-
CAS Number667880-38-8
-
分子量433.52
-
分子式C24H23N3O3S
-
纯度>98% (HPLC)
-
溶解度DMSO:62.5 mg/mL (144.17 mM; Need ultrasonic)
-
SMILESO=C(/C(C(N1)=O)=C/C2=C(C)N(CCOC3=CC=C(C)C=C3C)C4=C2C=CC=C4)NC1=S
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Zhang Y, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018 Jul 3;9(7):743.
产品手册
关联产品
-
Guaiol
(-)-Guaiol is a biocatalyst.
-
Isoliquiritin
Isoliquiritin, liquiritin and isoliquirigenin inhibits the p53-dependent pathway and shows crosstalk between Akt activities.
-
Cyanidin-3-O-arabino...
Cyanidin-3-O-arabinoside chloride has antioxidant activity. It reduces the peroxynitrite-induced suppression of mitochondrial respiration, DNA damage, PARS activation and vascular dysfunction in HUVECs.
